NCT00753688

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 369 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy

Conditions

• Sarcoma, Soft Tissue

Interventions

Type	Name	Description
DRUG	PAZOPANIB	800 mg once daily orally
DRUG	Placebo	matching placebo 800 mg once daily orally

Timeline

• Start date: 2008-10-01
• Primary completion: 2010-11-01
• Completion: 2012-12-01
• First posted: 2008-09-16
• Last updated: 2013-08-22
• Results posted: 2011-12-21

Locations

81 sites across 13 countries: United States, Australia, Belgium, Denmark, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, Sweden, United Kingdom